Pharma is one of the few sectors where market entry sequencing is inverted: regulatory approval has to come before commercial strategy, not alongside it. A distribution plan, a pricing model, a hospital partnership pipeline none of it can move ahead of CDSCO/DCGI product registration, because nothing is sellable until that clears. This guide lays out an India entry strategy for healthcare and pharma companies, weighted toward the pharma regulatory path since it’s the more complex and sequencing-sensitive of the two.
At a glance, this guide covers:
- Why regulatory approval gates everything else in pharma market entry
- CDSCO/DCGI product registration and how it varies by product category
- NPPA price caps and what they mean for margin planning before launch
- Choosing between export, joint venture, and local manufacturing
- Building distribution through local partners, hospitals, and pharmacy networks
- Verified market sizing for the segments worth prioritizing
Why Pharma Market Entry Starts With Regulatory Approval, Not Distribution
Unlike most sectors, a company entering India’s pharma market can’t build a distribution or partnership strategy before product registration is already underway CDSCO/DCGI approval gates everything commercial that follows it.
A few terms worth defining upfront:
- CDSCO (Central Drugs Standard Control Organisation) is India’s national regulatory body for pharmaceuticals and medical devices, operating under the Ministry of Health and Family Welfare.
- DCGI (Drug Controller General of India) is the head of CDSCO and the licensing authority for new drugs, clinical trials, and certain categories of medical devices.
- NPPA (National Pharmaceutical Pricing Authority) is the government body that regulates and caps the prices of essential medicines under India’s Drug Price Control Order.
Registering Your Product CDSCO and DCGI Approval
Every pharmaceutical product must be registered with the DCGI through CDSCO before commercial sale in India, and the approval route varies significantly by product category.
| Product Category | Approval Route | Typical Complexity |
| New drug (not previously approved in India) | Full DCGI clinical trial + approval process | High multi-phase trials often required |
| Generic drug | Abbreviated approval pathway referencing existing approvals | Moderate |
| Biologic | DCGI approval with additional biosimilar-specific requirements | High |
| Medical device | Risk-based classification (Class A–D) under Medical Device Rules | Varies by risk class |
Clinical trials and manufacturing facilities must meet both local CDSCO standards and global quality benchmarks simultaneously; a facility built only to one standard typically needs rework before it clears Indian approval, which is a costly discovery to make late in the process.
Pricing Compliance What NPPA Price Caps Mean for Market Entry
NPPA caps prices on medicines classified as essential under the Drug Price Control Order, and this has to be modeled into a company’s pricing and margin strategy before launch, not adjusted after the fact.
Illustrative example: A company planning to launch a product that falls under NPPA’s essential medicines list needs to model margins against the ceiling price from day one a product priced assuming open-market rates can find its actual permitted price significantly lower once it’s classified as scheduled, which changes the entire business case for entry. A non-scheduled product, by contrast, has considerably more pricing flexibility. Confirming a product’s likely NPPA classification early is a planning input, not a launch-week surprise.
Choosing Your Entry Model Export, Joint Venture, or Local Manufacturing
Three broad models exist, each with a different regulatory and capital profile and the right one for a given product often depends on how much local regulatory navigation and manufacturing presence the product category demands.
| Entry Model | Regulatory Complexity | Capital Intensity | Speed to Market |
| Export only | Lower product approval, but no local manufacturing licensing | Low | Fastest |
| Joint venture with an Indian partner | Moderate partner often has existing licenses/relationships | Moderate | Faster than solo entry |
| Local manufacturing | Higher facility licensing, quality certification | High | Slowest, but positions for scale |
Export-only entry makes sense for testing market demand with lower upfront commitment. A joint venture accelerates regulatory navigation and distribution access by leveraging a partner’s existing relationships and licenses this is where Transaction Advisory Services and M&A Due Diligence become directly relevant, since structuring the JV and vetting the partner’s regulatory and financial standing has to happen before the partnership is finalized, not after. Local manufacturing becomes worth the higher capital intensity for large-volume generics or where India’s production-linked incentive schemes make domestic manufacturing materially more attractive than importing.
Building Distribution Local Partners, Hospitals and Pharmacy Networks
Distribution in India runs through a layered network of agents, hospitals, and pharmacy chains rather than a direct-to-consumer model, and a joint venture or established local partner materially shortens the time it takes to build this network from scratch.
- Distributor selection– evaluate existing therapeutic-area relationships and geographic coverage, not just distribution capacity
- Hospital procurement relationships– private hospital chains and government procurement channels operate on different cycles and require separate relationship-building
- Regional pharmacy networks– retail pharma distribution varies significantly by state, making a single national distributor strategy less effective than regional partnerships in many cases
Where the Real Opportunity Is Market Segments Worth Prioritizing
India’s broader healthcare market is projected to grow from roughly $638 billion currently toward $1.5 trillion by 2030, according to Rubix Industry Insights; the pharmaceutical segment specifically is projected to grow from about $50 billion in FY23-24 to $130 billion by 2030, per Nexdigm’s industry research. Within that growth, a few segments stand out for prioritization:
- Chronic disease management– rising non-communicable disease burden is driving sustained demand
- Medical devices- India’s medtech sector is projected toward $35 billion by 2030, supported by export growth and domestic manufacturing incentives
- Retail pharma- expanding across both metro and secondary cities
- Digital health- among the fastest-growing segments, with strong CAGR through 2030
How KNM Is Already Helping Pharma and Healthcare Companies Enter India
We’ve worked with a mid-sized pharma company that chose a joint-venture entry model specifically to accelerate CDSCO navigation while building local manufacturing readiness in parallel; the JV partner’s existing licenses shortened the regulatory timeline considerably, while KNM handled the corporate and tax structuring of the partnership alongside it. This kind of parallel-track approach regulatory, corporate structuring, and India Business Setup work happening simultaneously rather than sequentially is typically what separates a fast entry from a slow one.
Talk to KNM Before Finalizing Your Entry Model
If your company is planning India market entry in healthcare or pharma, the entry model and regulatory filing sequence need to be decided together, not separately.
Reach out to KNM India to structure your entry model, JV due diligence, or manufacturing readiness plan before you commit to a timeline.
FAQs
What approvals does a foreign pharma company need before selling in India?
Products must be registered with the Drug Controller General of India (DCGI) through CDSCO before commercial sale, with the specific approval route depending on whether the product is a new drug, generic, biologic, or medical device.
How does NPPA pricing affect market entry planning?
The National Pharmaceutical Pricing Authority caps prices on medicines classified as essential, so companies need to model margins against potential price ceilings before launch, since a product’s NPPA classification can significantly change its viable pricing strategy.
What is the difference between exporting, a joint venture, and local manufacturing for India entry?
Exporting has the lowest capital intensity and fastest speed to market but limited local regulatory leverage; a joint venture accelerates regulatory navigation and distribution access through a partner’s existing licenses; local manufacturing requires the highest capital investment but positions a company for scale and can align with production-linked incentives.
Which healthcare segments in India are growing fastest?
Digital health and medical devices are among the fastest-growing segments, alongside chronic disease management and retail pharma expansion, within a broader healthcare market projected to reach roughly $1.5 trillion by 2030.
